Skip to main content
padlock icon - secure page this page is secure

Bevacizumab (Avastin) for the Treatment of Retinopathy of Prematurity

Buy Article:

$17.00 + tax (Refund Policy)

Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the eye that threatens to impair vision in premature infants.1 It is estimated that at least 50 percent of infants with a birth weight of <1,250 g develop ROP, with 10 percent progressing to Stage 3.2 Treatment modalities for ROP have evolved over the past two decades. Historically, treatment for ROP has ranged from cryotherapy in the 1980s to laser photocoagulation in the 1990s. Recent advances have expanded the options available for the treatment of ROP to include antivascular endothelial growth factor (anti-VEGF) therapy currently under investigation.3 This column describes the mechanism of action and review of the angiogenesis inhibitor, bevacizumab (Avastin), as a potential option for the treatment of ROP.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: July 1, 2012

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more